A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Cimaglermin alfa (Primary)
  • Indications Heart failure; Left ventricular dysfunction
  • Focus Adverse reactions; First in man
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 18 Mar 2017 Results (n=2) investigating cases of hepatotoxicity from two phase 1 trials (NCT01944683 and NCT01258387) meeting Hy's Law criteria, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 10 Mar 2015 According to an Acorda Therapeutics media release, data presented at the American College of Cardiology 64th Annual Scientific Session and Expo (ACC) 2015.
    • 11 Mar 2013 Results assessing preliminary efficacy presented at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top